Effect of KRAS gene mutation and clinical factors on postoperative prognosis of rectal cancer patients
10.3969/j.issn.1006-5725.2018.03.006
- VernacularTitle:直肠癌患者KRAS基因突变和临床因素对术后预后的影响
- Author:
Dongyang YANG
1
;
Dong MA
;
Wanwei LIU
;
Xiaorong LAI
;
Ying LI
;
Fan MENG
;
Zijun LI
;
Fei XU
Author Information
1. 广东省人民医院
- Keywords:
KRAS gene mutation;
rectal cencer surgery;
postoperative prognosis;
clinical charac-teristics
- From:
The Journal of Practical Medicine
2018;34(3):362-366
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of KRAS gene mutation and clinical factors on postopera-tive prognosis of rectal cancer patients and to explore their value in prognosis. Methods A total of 130 cases of rectal cancer patients from January to December 2010 were collected in the study. The tumor tissues sample was used to detect the KRAS gene mutation and 5-year follow-up was conducted. The correlation between KRAS gene mutation and clinical pathological features was analyzed.The clinic pathological factors that may affect the progno-sis were analyzed by survival analysis. Results Forty-five patients had mutations in No.2 expressed region of KRAS,with a mutation rate of 34.6%.KRAS gene mutation and stronger positive expression of EGFR(P<0.05), and multiple metastasis of tumor(P<0.05)were strongly coupled.The average survival of patients with wild-type KRAS gene was 57.5 months and that of patients with KRAS gene mutation 58.9 months but no significant differ-ence was observed(P>0.05).The TNM by high staging,multiple metastasis,lung metastasis and liver metasta-sis of cancer cells was closely related with poor postoperative prognosis of patients(P<0.05).The average surviv-al of postoperative patients in stage Ⅳ was 49months. Conclusions KRAS gene mutation in patients with rectal cancer after surgery is related with stronger positive expression of EGFR and multiple metastasis of cancer.TNM by high staging and metastatic sites affects the prognosis. The survival of rectal cancer after surgery in patients with stage Ⅳ are prolonged but the relation between KRAS genovariation and patients′ postoperative prognosis can not be determined.
